In the BioHarmony Drug Report Database
Tafluprost
Zioptan (tafluprost) is a small molecule pharmaceutical. Tafluprost was first approved as Zioptan on 2012-02-10. It is used to treat open-angle glaucoma in the USA. The pharmaceutical is active against prostaglandin F2-alpha receptor. Zioptan’s patents are valid until 2029-05-28 (FDA).
Trade Name
|
Zioptan |
|---|---|
Common Name
|
tafluprost |
ChEMBL ID
|
CHEMBL1963683 |
Indication
|
open-angle glaucoma |
Drug Class
|
Prostaglandins |
Image (chem structure or protein)